SCHEMBL21652036

SCHEMBL21652036

CSCN1CC(OCc2ccccn2)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 1/20 0.44
SIGMAR1 Q99720 1/20 0.44
ALDH1A1 P00352 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
LPL P06858 1/20 0.41
LIPC P11150 1/20 0.41
LIPG Q9Y5X9 1/20 0.41
SYK P43405 3/20 0.38
LMNA P02545 2/20 0.38
RET P07949 1/20 0.37
AURKB Q96GD4 2/20 0.36
INCENP Q9NQS7 2/20 0.36
MEN1 O00255 1/20 0.36
PABPC1 P11940 1/20 0.36
KMT2A Q03164 1/20 0.36
PRMT5 O14744 1/20 0.36
WDR77 Q9BQA1 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21652008 0.78 CTSL (0.54) SIGMAR1ALDH1A1LMNA
SCHEMBL20068997 0.77 DRD4 (0.43) DRD4SIGMAR1ALDH1A1L3MBTL1LPL
SCHEMBL20158640 0.75 DRD4 (0.41) DRD4SIGMAR1ALDH1A1L3MBTL1LPL
SCHEMBL7016474 0.74 CTSL (0.61)
SCHEMBL20068999 0.72 SIGMAR1 (0.55) DRD4SIGMAR1ALDH1A1L3MBTL1LPL
SCHEMBL15477305 0.72 DRD4 (0.51) DRD4SIGMAR1ALDH1A1L3MBTL1LPL
SCHEMBL28660573 0.71 SLC6A4 (0.56) DRD4SIGMAR1ALDH1A1LPLLIPC
SCHEMBL8160070 0.71 LPL (0.54) DRD4SIGMAR1ALDH1A1L3MBTL1LPL
SCHEMBL21652059 0.70 DRD4 (0.41) DRD4RET
SCHEMBL3968962 0.70 SYK (0.46) ALDH1A1SYKLMNAAURKBINCENP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200383966-A9 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2020-12-10 US disclosed
US-20200030311-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA, INC. 2020-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200383966-A9 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 DRD4 2952/4885SIGMAR1 3807/4885ALDH1A1 2547/4885
US-20200030311-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 DRD4 2952/4885SIGMAR1 3807/4885ALDH1A1 2547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.